Kalaris Therapeutics (KLRS) director receives stock options for 9,000 shares

Rhea-AI Filing Summary

Kalaris Therapeutics director David Hallal received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and was granted as compensation rather than a market purchase.

The option was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, conditioned on his continued service. Following this grant, Hallal holds options for 9,000 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hallal David

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 9,000 shares Exercise price: $4.72 per share Expiration date: June 2, 2036

3 metrics

Option grant size 9,000 shares Stock Option (Right to Buy) granted to director

Exercise price $4.72 per share Conversion/exercise price for the 9,000-share option

Expiration date June 2, 2036 Option expiration for Hallal’s grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.7200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying the option are scheduled to vest in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders financial

"earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hallal David

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.72	06/03/2026		A		9,000		(1)	06/02/2036	Common Stock	9,000	$0	9,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brett Hagen, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kalaris Therapeutics (KLRS) director David Hallal report on this Form 4?

David Hallal reported receiving a stock option grant for 9,000 shares of Kalaris Therapeutics common stock. The grant is compensation-related, not an open-market share purchase, and gives him the right to buy shares at a fixed exercise price in the future.

How many Kalaris Therapeutics (KLRS) shares are covered by Hallal’s new option grant?

The option grant covers 9,000 shares of Kalaris Therapeutics common stock. These options give Hallal the right to acquire up to 9,000 shares if he chooses to exercise them after vesting, subject to the specified exercise price and expiration date.

What is the exercise price and expiration date of David Hallal’s KLRS stock options?

The options have an exercise price of $4.72 per share and expire on June 2, 2036. This means Hallal can choose to buy up to 9,000 shares at $4.72 any time after vesting and before the June 2036 expiration.

When do David Hallal’s Kalaris Therapeutics (KLRS) options vest?

The options are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting. Vesting is subject to Hallal’s continued service with Kalaris Therapeutics through that date, according to the filing footnote.

Is Hallal’s KLRS Form 4 transaction a market buy or sell of shares?

The Form 4 reports a grant of stock options, not a market buy or sell of common shares. Code “A” indicates a grant or award acquisition, reflecting compensation rather than an open-market transaction that would directly change public float.

How many Kalaris Therapeutics (KLRS) options does Hallal hold after this grant?

After this grant, Hallal directly holds options representing 9,000 underlying shares of Kalaris Therapeutics common stock. The filing’s totals reflect this new award and show no additional derivative positions reported beyond this grant in the current Form 4.